Listening to the Patient Voice Adds Value to Cancer Clinical Trials

• Published in: JNCI : Journal of the National Cancer Institute 2022-10, Vol.114 (10), p.1323-1332
• Main Authors: Brundage, Michael D, Crossnohere, Norah L, O'Donnell, Jennifer, Cruz Rivera, Samantha, Wilson, Roger, Wu, Albert W, Moher, David, Kyte, Derek, Reeve, Bryce B, Gilbert, Alexandra, Chen, Ronald C, Calvert, Melanie J, Snyder, Claire
• Format: Article
• Language: English
• Subjects: Commentaries; Drug Development; Editor's Choice; Health Policy; Humans; Neoplasms - therapy; Patient Reported Outcome Measures
• ISSN: 0027-8874; 1460-2105
• DOI: 10.1093/jnci/djac128

Randomized clinical trials are critical for evaluating the safety and efficacy of interventions in oncology and informing regulatory decisions, practice guidelines, and health policy. Patient-reported outcomes (PROs) are increasingly used in randomized trials to reflect the impact of receiving cancer therapies from the patient perspective and can inform evaluations of interventions by providing evidence that cannot be obtained or deduced from clinicians' reports or from other biomedical measures. This commentary focuses on how PROs add value to clinical trials by representing the patient voice. We employed 2 previously published descriptive frameworks (addressing how PROs are used in clinical trials and how PROs have an impact, respectively) and selected 9 clinical trial publications that illustrate the value of PROs according to the framework categories. These include 3 trials where PROs were a primary trial endpoint, 3 trials where PROs as secondary endpoints supported the primary endpoint, and 3 trials where PROs as secondary endpoints contrast the primary endpoint findings in clinically important ways. The 9 examples illustrate that PROs add valuable data to the care and treatment context by informing future patients about how they may feel and function on different treatments and by providing clinicians with evidence to support changes to clinical practice and shared decision making. Beyond the patient and clinician, PROs can enable administrators to consider the cost-effectiveness of implementing new interventions and contribute vital information to policy makers, health technology assessors, and regulators. These examples provide a strong case for the wider implementation of PROs in cancer trials.